Telomir Pharmaceuticals, Inc.

Analysis for Ticker: TELO

Telomir Pharmaceuticals Inc is a business that claims to be a biotechnology company focused on treating the biological causes of aging and degenerative diseases. The company is walking into a massive financial trap because they just received government permission to start a human clinical trial that they cannot afford to finish. The math is a disaster because the company is carrying the weight of almost seventy-six million shares while trying to fund a trial for seventy-six patients using only a tiny 1$ million cash lifeline from its largest shareholder. Think of it like trying to fly a giant airplane across the ocean with only one gallon of fuel; the plane is simply too heavy and the tank is too empty to reach the other side. The chief executive officer and the founder's family trust have already positioned themselves to take more equity and cash the moment any progress is made, leaving the public shareholders to pay for the entire expensive flight while their own ownership percentage is crushed into smaller and smaller pieces.